OBJECTIVE: There is little information on the duration of time that patients spend off therapy (down-time) during continuous veno-venous haemofiltration (CVVH) and the effect of this treatment free time on azotaemic control. DESIGN AND SETTING: Prospective observational study in the ICU of tertiary hospital. PATIENTS AND PARTICIPANTS: 48 critically ill patients treated with CVVH at 2 l/h of ultrafiltration. INTERVENTIONS: Prospective collection of demographic and biochemical data. MEASUREMENTS AND RESULTS: Two hundred and sixty-six filters were observed. Start and end times were collected for each filter. Creatinine and urea were measured daily and percentage of reduction of these two solutes was calculated (%Delta creatinine and urea). The median period when CVVH was not applied to a patient (down-time) was 3 h per day. There was a significant inverse correlation between down-time and %Delta creatinine and urea over each 24-h time cycle. On average at least 16 h per day of CVVH was required to maintain creatinine and urea concentration for each 24-h cycle. CONCLUSIONS: "Continuous" therapy is not truly continuous. Down-time adversely affects azotaemic control. Physicians prescribing CRRT should be aware of the consequences of such down-time on the quality and quantity of renal replacement therapy delivered.
OBJECTIVE: There is little information on the duration of time that patients spend off therapy (down-time) during continuous veno-venous haemofiltration (CVVH) and the effect of this treatment free time on azotaemic control. DESIGN AND SETTING: Prospective observational study in the ICU of tertiary hospital. PATIENTS AND PARTICIPANTS: 48 critically illpatients treated with CVVH at 2 l/h of ultrafiltration. INTERVENTIONS: Prospective collection of demographic and biochemical data. MEASUREMENTS AND RESULTS: Two hundred and sixty-six filters were observed. Start and end times were collected for each filter. Creatinine and urea were measured daily and percentage of reduction of these two solutes was calculated (%Delta creatinine and urea). The median period when CVVH was not applied to a patient (down-time) was 3 h per day. There was a significant inverse correlation between down-time and %Delta creatinine and urea over each 24-h time cycle. On average at least 16 h per day of CVVH was required to maintain creatinine and urea concentration for each 24-h cycle. CONCLUSIONS: "Continuous" therapy is not truly continuous. Down-time adversely affects azotaemic control. Physicians prescribing CRRT should be aware of the consequences of such down-time on the quality and quantity of renal replacement therapy delivered.
Authors: Nguyen Hoan Phu; Tran Tinh Hien; Nguyen Thi Hoang Mai; Tran Thi Hong Chau; Ly Van Chuong; Pham Phu Loc; Christopher Winearls; Jeremy Farrar; Nicholas White; Nicholas Day Journal: N Engl J Med Date: 2002-09-19 Impact factor: 91.245
Authors: J van de Wetering; R G Westendorp; J G van der Hoeven; B Stolk; J D Feuth; P C Chang Journal: J Am Soc Nephrol Date: 1996-01 Impact factor: 10.121
Authors: Edward Abraham; Peter Andrews; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Michael Pinsky; Peter Radermacher; Marco Ranieri; Christian Richard; Robert Tasker; Benoit Vallet Journal: Intensive Care Med Date: 2004-06-15 Impact factor: 17.440
Authors: Stanislav S Dukhin; Yacoob Tabani; Richard Lai; Omar A Labib; Andrew L Zydney; Mohamed E Labib Journal: J Memb Sci Date: 2014-08-15 Impact factor: 8.742
Authors: Aadil Kakajiwala; Thomas Jemielita; John Z Hughes; Kimberly Windt; Michelle Denburg; Stuart L Goldstein; Benjamin Laskin Journal: Pediatr Nephrol Date: 2017-03-01 Impact factor: 3.714